M. Castiglione‐Gertsch

发表

Adjuvant endocrine therapy compared with no systemic therapy for elderly women with early breast cancer: 21-year results of International Breast Cancer Study Group Trial IV.

R. Gelber, A. Goldhirsch, J. Collins, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

C. Perou, E. Winer, J. Forbes, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Patterns of Recurrence and outcome according to breast cancer subtypes in lymph node-negative disease: results from international breast cancer study group trials VIII and IX.

R. Gelber, A. Goldhirsch, F. Cardoso, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial.

M. Bonetti, R. Gelber, A. Goldhirsch, 2002, Journal of the National Cancer Institute.

Impact of adjuvant therapy on quality of life in women with node-positive operable breast cancer

J. Forbes, A. Goldhirsch, C. Hürny, 1996, The Lancet.

Role of immunohistochemical detection of lymph-node metastases in management of breast cancer

B. Gusterson, R. Cote, A. Goldhirsch, 1999, The Lancet.

Tubular carcinoma of the breast: Prognosis and response to adjuvant systemic therapy

R. Gelber, B. Gusterson, A. Goldhirsch, 2001, ANZ journal of surgery.

Adjuvant chemoendocrine therapy in postmenopausal breast cancer: cyclophosphamide, methotrexate, and fluorouracil dose and schedule may make a difference. International Breast Cancer Study Group.

R. Gelber, A. Goldhirsch, A. Coates, 1998, Journal of Clinical Oncology.

Adding adjuvant CMF chemotherapy to either radiotherapy or tamoxifen: are all CMFs alike? The International Breast Cancer Study Group (IBCSG).

R. Gelber, A. Goldhirsch, A. Coates, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays.

R. Gelber, L. Mazzucchelli, B. Gusterson, 2006, Journal of the National Cancer Institute.

Adjuvant treatment of breast cancer: sequence and duration of hormonal therapy.

M. Castiglione‐Gertsch, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Adjuvant endocrine therapies for postmenopausal women with early breast cancer: standards and not.

M. Castiglione‐Gertsch, S. Dellapasqua, 2005, Breast.

Adjuvant pegylated liposomal doxorubicin for older women with endocrine nonresponsive breast cancer who are NOT suitable for a "standard chemotherapy regimen": the CASA randomized trial.

R. Gelber, A. Goldhirsch, M. Regan, 2013, Breast.

Role of hormonal manipulations in patients with hormone-sensitive metastatic breast cancer.

M. Castiglione‐Gertsch, A. Bodmer, 2011, European journal of cancer.

Long-term results of International Breast Cancer Study Group Trial VIII: adjuvant chemotherapy plus goserelin compared with either therapy alone for premenopausal patients with node-negative breast cancer.

R. Gelber, B. Gusterson, A. Goldhirsch, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Systemic adjuvant treatment for premenopausal node-negative breast cancer. The International Breast Cancer Study Group.

R. Gelber, A. Goldhirsch, A. Coates, 2000, European journal of cancer.

Mortality during adjuvant treatment of early breast cancer with cyclophosphamide, methotrexate, and fluorouracil

R. Gelber, A. Coates, K. Price, 1999, The Lancet.

Hormone replacement and breast cancer.

M. Castiglione‐Gertsch, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer

J. Forbes, R. Gelber, A. Goldhirsch, 2007, British Journal of Cancer.

Leukemia Risk after Adjuvant Treatment of Early Breast Cancer

M. Castiglione‐Gertsch, A. Balduzzi, 2005 .

Leukemia risk after adjuvant treatment of early breast cancer.

M. Castiglione‐Gertsch, A. Balduzzi, 2005, Women's health.

Factors affecting baseline quality of life in two international adjuvant breast cancer trials. International Breast Cancer Study Group (IBCSG).

J. Forbes, R. Gelber, A. Goldhirsch, 1998, British Journal of Cancer.

The International (Ludwig) Breast Cancer Study Group Trials I-IV: 15 years follow-up.

J. Forbes, F. Cavalli, R. Gelber, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: first results of International Breast Cancer Study Group Trial 10-93.

J. Forbes, R. Gelber, A. Goldhirsch, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Why did the study fail?

M. Castiglione‐Gertsch, S. Dellapasqua, 2005, European journal of cancer.

Prognostic importance of thymidylate synthase expression in early breast cancer.

R. Gelber, B. Gusterson, P. Johnston, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

E9. Update on systemic adjuvant treatment

M. Castiglione‐Gertsch, 2004 .

Relation between chemotherapy dose, oestrogen receptor expression, and body-mass index

R. Gelber, A. Goldhirsch, A. Coates, 2005, The Lancet.

Dose-response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer. International Breast Cancer Study Group.

A. Goldhirsch, A. Coates, B. Thürlimann, 1998, European journal of cancer.

Defining clinical benefit in postmenopausal patients with breast cancer under second-line endocrine treatment: does quality of life matter?

F. Cavalli, A. Goldhirsch, C. Hürny, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Decreased immunoreactivity for p27 protein in patients with early‐stage breast carcinoma is correlated with HER‐2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status

R. Gelber, B. Gusterson, A. Goldhirsch, 2003, Cancer.

First-line fadrozole HCI (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer. Prospective randomised trial of the Swiss Group for Clinical Cancer Research SAKK 20/88.

F. Cavalli, A. Goldhirsch, B. Thürlimann, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

Early studies establishing the predictive and prognostic value of steroid hormone receptors measured levels of ER and PgR in Background: Tumor levels of steroid hormone receptors, a factor used to select adjuvant treatment for early-stage breast

R. Gelber, L. Mazzucchelli, B. Gusterson, 2006 .

Ovarian ablation, a perennial technique still not well understood

M. Castiglione‐Gertsch, S. Dellapasqua, 2005, Nature Clinical Practice Oncology.

Quantifying trade-offs: quality of life and quality-adjusted survival in a randomised trial of chemotherapy in postmenopausal patients with lymph node-negative breast cancer

J. Forbes, R. Gelber, A. Goldhirsch, 2004, British Journal of Cancer.

Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: Updated safety analysis of trial BIG 1–98

A. Coates, B. Thürlimann, L. Mauriac, 2007 .

Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from trial BIG 1-98 comparing adjuvant endocrine therapy with tamoxifen versus letrozole

A. Giobbie-Hurder, P. Neven, B. Gusterson, 2008 .

Quality of life assessment in International Breast Cancer Study Group (IBCSG) trials: practical issues and factors associated with missing data.

R. Gelber, C. Hürny, J. Bernhard, 1998, Statistics in Medicine.

Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.

J. Forbes, R. Gelber, R. Paridaens, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Quality of life assessment in patients receiving adjuvant therapy for breast cancer: the IBCSG approach. The International Breast Cancer Study Group.

R. Gelber, A. Goldhirsch, C. Hürny, 1997, Annals of Oncology.

Dose–response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer

A. Goldhirsch, A. Coates, B. Thürlimann, 1998 .

Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial.

J. Forbes, R. Gelber, R. Paridaens, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII.

F. Cavalli, M. Bonetti, R. Gelber, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial.

J. Forbes, R. Gelber, R. Paridaens, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Capecitabine and vinorelbine in elderly patients (> or =65 years) with metastatic breast cancer: a phase I trial (SAKK 25/99).

A. Goldhirsch, B. Thürlimann, M. Castiglione‐Gertsch, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognostic and predictive impact of central necrosis and fibrosis in early breast cancer: Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy

R. Gelber, A. Goldhirsch, G. Viale, 2010, Breast Cancer Research and Treatment.

New aromatase inhibitors: more selectivity, less toxicity, unfortunately, the same activity.

M. Castiglione‐Gertsch, 1996, European journal of cancer.

A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.

J. Forbes, R. Gelber, R. Paridaens, 2005, The New England journal of medicine.

Patterns and risk factors for locoregional failures after mastectomy for breast cancer: an International Breast Cancer Study Group report.

J. Forbes, R. Gelber, A. Goldhirsch, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Retreating recurrent breast cancer with the same CMF-containing regimen used as adjuvant therapy. The International Breast Cancer Study Group.

M. Tattersall, R. Gelber, A. Goldhirsch, 1997, European journal of cancer.

High-dose chemotherapy for ovarian cancer: are we ready to go?

M. Castiglione‐Gertsch, S. Aebi, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

S24 Adjuvant Endocrine Therapies for PostmenopausalWomen: Standards and Not

M. Castiglione‐Gertsch, 2005 .

Adjuvant chemotherapy in elderly patients with breast cancer: a survey of the Breast International Group (BIG).

M. Piccart, P. Therasse, A. Goldhirsch, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognostic value of extracapsular tumor spread for locoregional control in premenopausal patients with node-positive breast cancer treated with classical cyclophosphamide, methotrexate, and fluorouracil: long-term observations from International Breast Cancer Study Group Trial VI.

M. Bonetti, R. Gelber, A. Goldhirsch, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience.

A. Goldhirsch, J. Collins, A. Coates, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Risk factors for locoregional recurrence among breast cancer patients: results from International Breast Cancer Study Group Trials I through VII.

J. Forbes, M. Bonetti, R. Gelber, 2003, Journal of Clinical Oncology.

First year experience with IORT for breast cancer at the Geneva University Hospitals

R. Miralbell, M. Castiglione‐Gertsch, V. Vinh-Hung, 2014 .

Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole.

A. Giobbie-Hurder, P. Neven, R. Gelber, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ki‐67 expression in breast carcinoma

R. Gelber, B. Gusterson, A. Goldhirsch, 2003, Cancer.

Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials.

R. Gelber, B. Gusterson, A. Goldhirsch, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant therapy for very young women with breast cancer: need for tailored treatments.

R. Gray, R. Gelber, J. Bryant, 2001, Journal of the National Cancer Institute. Monographs.

Effect of pregnancy on overall survival after the diagnosis of early-stage breast cancer.

R. Gelber, A. Goldhirsch, A. Coates, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect o f P regnancy o n O verall S urvival A fter t he Diagnosis o f E arly-Stage B reast C ancer

R. Gelber, A. Goldhirsch, A. Coates, 2001 .

Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.

R. Gelber, M. Buyse, A. Goldhirsch, 2008, Journal of the National Cancer Institute.

Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG).

R. Gelber, A. Goldhirsch, J. Collins, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12–93

J. Forbes, R. Gelber, A. Goldhirsch, 2009, Breast Cancer Research and Treatment.

Effects of a treatment gap during adjuvant chemotherapy in node-positive breast cancer: results of International Breast Cancer Study Group (IBCSG) Trials 13-93 and 14-93.

R. Gelber, A. Goldhirsch, A. Coates, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93.

R. Gelber, A. Goldhirsch, A. Coates, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multicycle dose-intensive chemotherapy for women with high-risk primary breast cancer: results of International Breast Cancer Study Group Trial 15-95.

R. Gelber, A. Goldhirsch, A. Coates, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Timing of CMF chemotherapy in combination with tamoxifen in postmenopausal women with breast cancer: role of endocrine responsiveness of the tumor.

A. Goldhirsch, J. Collins, A. Coates, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Toremifene and tamoxifen are equally effective for early-stage breast cancer: first results of International Breast Cancer Study Group Trials 12-93 and 14-93.

R. Gelber, A. Goldhirsch, D. Zahrieh, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial.

M. Bonetti, R. Gelber, A. Goldhirsch, 2003, Journal of the National Cancer Institute.

Adjuvant therapy after excision and radiation of isolated postmastectomy locoregional breast cancer recurrence: definitive results of a phase III randomized trial (SAKK 23/82) comparing tamoxifen with observation.

A. Goldhirsch, B. Thürlimann, M. Castiglione‐Gertsch, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Influence of endocrine-related factors on response to perioperative chemotherapy for patients with node-negative breast cancer.

R. Gelber, A. Goldhirsch, A. Coates, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Influence o f E ndocrine-Relate d F actors o n R esponse t o Perioperative C hemotherapy f or P atients W ith N ode- Negative B reast C ancer

R. Gelber, A. Coates, M. Castiglione‐Gertsch, 2001 .

Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer?

R. Gelber, A. Goldhirsch, A. Coates, 2000, The Lancet.

Adverse prognostic value of peritumoral vascular invasion: is it abrogated by adequate endocrine adjuvant therapy? Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy for early breast cancer.

A. Giobbie-Hurder, R. Gelber, B. Gusterson, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

The importance of the histologic grade of invasive breast carcinoma and response to chemotherapy

S. Pinder, B. Gusterson, C. Elston, 1998, Cancer.

The effect of adjuvant prednisone combined with CMF on patterns of relapse and occurrence of second malignancies in patients with breast cancer. International (Ludwig) Breast Cancer Study Group.

J. Forbes, F. Cavalli, R. Gelber, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer.

R. Gelber, B. Gusterson, A. Goldhirsch, 2008, Journal of the National Cancer Institute.

Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.

R. Gelber, B. Gusterson, A. Goldhirsch, 2008, The Lancet. Oncology.

Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98.

P. Neven, R. Gelber, B. Gusterson, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors. The International Breast Cancer Study Group.

M. Bonetti, R. Gelber, A. Goldhirsch, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

p27 and Skp2 immunoreactivity and its clinical significance with endocrine and chemo-endocrine treatments in node-negative early breast cancer.

F. Monti, B. Gusterson, A. Goldhirsch, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Cutaneous Metastasis of Endometrial Carcinoma: A Case Report and Literature Review

A. Hottinger, M. Castiglione‐Gertsch, J. Tille, 2012 .

Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: long-term follow up on IBCSG Trial IX.

R. Gelber, B. Gusterson, A. Goldhirsch, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognostic and Predictive Value of Centrally Reviewed Expression of Estrogen and Progesterone Receptors in a Randomized Trial Comparing Letrozole and Tamoxifen Adjuvant Therapy for Postmenopausal Early Breast Cancer : BIG 198

P. Neven, R. Gelber, B. Gusterson, 2007 .

Tailoring adjuvant treatments for the individual breast cancer patient.

M. Bonetti, R. Gelber, A. Goldhirsch, 2003, Breast.

Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients--the International Breast Cancer Study Group Trial VIII.

J. Forbes, R. Gelber, A. Goldhirsch, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial.

J. Forbes, R. Gelber, R. Paridaens, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

BIG 1-98: A randomized double-blind phase III study comparing letrozole and tamoxifen given in sequence vs. alone as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer.

J. Forbes, R. Gelber, R. Paridaens, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Responsiveness of a single-item indicator versus a multi-item scale: assessment of emotional well-being in an international adjuvant breast cancer trial.

R. Gelber, A. Goldhirsch, C. Hürny, 1996, Medical care.

Secretory breast cancer in a 7.5-year old boy.

Z. Szentirmay, M. Castiglione‐Gertsch, J. Szántó, 2004, Breast.

Controversies of adjuvant endocrine treatment for breast cancer and recommendations of the 2007 St Gallen conference.

M. Castiglione‐Gertsch, S. Aebi, M. Rabaglio, 2007, The Lancet. Oncology.

15 Timing of radiotherapy (RT) and chemotherapy (CT) following breast conserving surgery (BCS) for patients with node-positive breast cancer

R. Gelber, M. Castiglione‐Gertsch, J. Bernier, 1995 .

Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.

R. Gelber, B. Gusterson, A. Goldhirsch, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial.

J. Forbes, R. Gelber, R. Paridaens, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Quality-of-life scores predict outcome in metastatic but not early breast cancer. International Breast Cancer Study Group.

R. Gelber, A. Goldhirsch, C. Hürny, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Second non-breast primary cancer following adjuvant therapy for early breast cancer: a report from the International Breast Cancer Study Group.

R. Gelber, A. Goldhirsch, A. Coates, 2009, European journal of cancer.

New treatments for breast cancer: breakthroughs for patient care or just steps in the right direction?

R. Gelber, A. Goldhirsch, A. Coates, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

Site of primary tumor has a prognostic role in operable breast cancer: the international breast cancer study group experience.

R. Gelber, A. Goldhirsch, J. Collins, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The choice of systemic adjuvant therapy in receptor-positive early breast cancer.

M. Castiglione‐Gertsch, S. Dellapasqua, 2005, European journal of cancer.

Duration of adjuvant chemotherapy for breast cancer: a joint analysis of two randomised trials investigating three versus six courses of CMF

M. Bonetti, R. Gelber, W. Sauerbrei, 2002, British Journal of Cancer.

Risk factors for locoregional recurrence among breast cancer patients: results from International Breast Cancer Study Group Trials I through VII.

J. Forbes, M. Bonetti, R. Gelber, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Estrogen Receptor Modulators and Down Regulators

M. Castiglione‐Gertsch, C. K. Baumann, 2012, Drugs.

Primary endocrine therapy for advanced breast cancer: to start with tamoxifen or with medroxyprogesterone acetate?

A. Goldhirsch, H. Senn, M. Castiglione‐Gertsch, 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

The role of the number of uninvolved lymph nodes in predicting locoregional recurrence in breast cancer.

J. Forbes, R. Gelber, B. Gusterson, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Age of menopause among women who remain premenopausal following treatment for early breast cancer: long-term results from International Breast Cancer Study Group Trials V and VI.

E. Winer, R. Gelber, A. Goldhirsch, 2007, European journal of cancer.

Risk F actors f or L ocoregional R ecurrence A mong B reast Cancer P atients: R esults F rom I nternational B reast C ancer Study G roup T rials I T hrough V II

M. Bonetti, A. Goldhirsch, J. Collins, 2003 .

Prognostic interaction between expression of p53 and estrogen receptor in patients with node-negative breast cancer: results from IBCSG Trials VIII and IX

R. Gelber, B. Gusterson, A. Goldhirsch, 2012, Breast Cancer Research.

How to improve timing and duration of adjuvant chemotherapy

R. Gelber, A. Coates, M. Castiglione‐Gertsch, 2001 .

Estrogen receptor modulators and down regulators: optimal use in postmenopausal women with breast cancer.

M. Castiglione‐Gertsch, C. K. Baumann, 2007, Drugs.

Timing of radiotherapy and chemotherapy following breast-conserving surgery for patients with node-positive breast cancer. International Breast Cancer Study Group.

R. Gelber, A. Goldhirsch, M. Castiglione‐Gertsch, 1996, International journal of radiation oncology, biology, physics.

Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy?

E. Perez, A. Goldhirsch, M. Regan, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Identifying B reast C ancer P atients a t H igh R isk f or Bone M etastases

F. Cavalli, M. Bonetti, R. Gelber, 2000 .

Timing of radiotherapy and outcome in patients receiving adjuvant endocrine therapy.

A. Goldhirsch, K. Price, M. Castiglione‐Gertsch, 2011, International journal of radiation oncology, biology, physics.

Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93

J. Forbes, R. Gelber, A. Goldhirsch, 2008, Breast Cancer Research and Treatment.

Adjuvant Chemotherapy for Locoregional Recurrent Breast Cancer

Joseph P. Costantino, Stewart J. Anderson, Norman Wolmark, 2011 .

A randomized clinical trial of adjuvant chemotherapy for radically resected locoregional relapse of breast cancer: IBCSG 27-02, BIG 1-02, and NSABP B-37.

R. Gelber, M. Piccart, J. Costantino, 2008, Clinical breast cancer.

P82 Tailored chemotherapy trial for women at advancedage with endocrine nonresponsive breast cancer: the CASA Trial

R. Gelber, A. Goldhirsch, M. Castiglione‐Gertsch, 2005 .

Adjuvant endocrine therapy for the very young patients.

M. Castiglione‐Gertsch, S. Aebi, 2003, Breast.

Quality of life assessment in patients receiving adjuvant therapy for breast cancer: The IBCSG approach

R. Gelber, A. Goldhirsch, C. Hürny, 1998 .

Chemo-endocrine therapy: Any need to combine?

M. Castiglione‐Gertsch, 2003 .

Taxanes as adjuvant for breast cancer

R. Gelber, A. Goldhirsch, P. Francis, 2000, The Lancet.

Quality of life scores predict outcome in metastatic but not in early breast cancer

R. Gelber, A. Goldhirsch, C. Hürny, 2001 .

Anemia during adjuvant non-taxane chemotherapy for early breast cancer: Incidence and risk factors from two trials of the International Breast Cancer Study Group

A. Goldhirsch, A. Coates, D. Crivellari, 2007, Supportive Care in Cancer.

Patterns of recurrence of early breast cancer according to estrogen receptor status: a therapeutic target for a quarter of a century

R. Gelber, A. Goldhirsch, J. Collins, 2009, Breast Cancer Research and Treatment.

Quality of life in postmenopausal patients with breast cancer after failure of tamoxifen: formestane versus megestrol acetate as second-line hormonal treatment. Swiss Group for Clinical Cancer Research (SAKK).

F. Cavalli, A. Goldhirsch, C. Hürny, 1999, European journal of cancer.

Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer.

R. Stupp, R. Herrmann, A. Goldhirsch, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I I S tudy o f C apecitabine a nd O xaliplatin i n F irst- and S econd-Line T reatment o f A dvanced o r M etastatic Colorectal C ancer

R. Stupp, R. Herrmann, A. Goldhirsch, 2002 .

Identifying breast cancer patients at high risk for bone metastases.

F. Cavalli, M. Bonetti, R. Gelber, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tailored treatment investigations for premenopausal women with endocrine responsive (ER+ and/or PgR+) breast cancer: The open questions

R. Gelber, A. Goldhirsch, A. Coates, 2003 .

A risk score based on histopathological features predicts higher risk of distant recurrence in premenopausal patients with lymph node-negative endocrine-responsive breast cancer.

R. Gelber, A. Goldhirsch, G. Viale, 2012, Breast.

Effect of Pregnancy on Overal l Surv iva l Af ter the Diagnosis of Ear ly-Stage Breast Cancer

R. Gelber, A. Goldhirsch, A. Coates, 2001 .

Special issues of systemic treatments

H. Dvorak, M. Castiglione‐Gertsch, M. Colleoni, 2002 .

Adjuvant systemic therapy: the issues of timing and sequence.

R. Gelber, A. Goldhirsch, M. Castiglione‐Gertsch, 1996, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Family History and Prognosis of Patients with Node-Positive Breast Cancer Treated with Adjuvant Therapy

R. Gelber, A. Goldhirsch, M. Castiglione‐Gertsch, 1990 .

p 27 and Skp 2 immunoreactivity and its clinical significance with endocrine and chemo-endocrine treatments in node-negative early breast cancer

F. Monti, B. Gusterson, A. Goldhirsch, 2009 .

Extracapsular tumor spread and the risk of local, axillary and supraclavicular recurrence in node-positive, premenopausal patients with breast cancer.

R. Gelber, B. Gusterson, A. Goldhirsch, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Features that predict responsiveness to chemotherapy and endocrine therapies

M. Bonetti, R. Gelber, A. Goldhirsch, 2001 .

Ocular toxicity during adjuvant chemoendocrine therapy for early breast cancer

R. Gelber, A. Goldhirsch, A. Coates, 2006, Cancer.

BIG 1-98: Randomized double-blind phase III study to evaluate letrozole (L) vs. tamoxifen (T) as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer

J. Forbes, R. Gelber, R. Paridaens, 2005 .

Effect of Pregnancy on Overall Survival After the Diagnosis of Early-Stage Breast Cancer

R. Gelber, A. Goldhirsch, A. Coates, 2001 .

[Breast cancer and obesity, a dangerous relation].

K. Zaman, M. Castiglione‐Gertsch, F. Pralong, 2012, Revue medicale suisse.

Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience.

A. Goldhirsch, J. Collins, A. Coates, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognostic interaction between expression of p53 and estrogen receptor in patients with node-negative breast cancer: results from IBCSG Trials VIII and IX

R. Gelber, B. Gusterson, A. Goldhirsch, 2012, Breast Cancer Research.

Patterns of Recurrence and outcome according to breast cancer subtypes in lymph node-negative disease: results from international breast cancer study group trials VIII and IX.

R. Gelber, A. Goldhirsch, F. Cardoso, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG).

R. Gelber, A. Goldhirsch, J. Collins, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Role of immunohistochemical detection of lymph-node metastases in management of breast cancer. International Breast Cancer Study Group.

M. Castiglione‐Gertsch, R. Gelber, A. Goldhirsch, 1999, Lancet.

Quality of life assessment in patients receiving adjuvant therapy for breast cancer: the IBCSG approach. The International Breast Cancer Study Group.

R. Gelber, A. Goldhirsch, C. Hürny, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

Role of hormonal manipulations in patients with hormone-sensitive metastatic breast cancer.

M. Castiglione‐Gertsch, A. Bodmer, 2011, European journal of cancer.

Early S tart o f A djuvant C hemotherapy M ay I mprove Treatment O utcome f or P remenopausal B reast C ancer Patients W ith T umors n ot E xpressing E strogen R eceptors

M. Bonetti, R. Gelber, A. Coates, 2000 .